EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitMetaanalyseOpen Access · CC BY 4.0

Cardiovascular Risk in Pancreatic Cancer: A Meta-Analysis of 197 Studies

Jázmin Németh, Jimin Lee iD, Orsolya Eperjesi, Endre Botond Gagyi iD, Zoltán Bánfalvi iD, Veronika Lillik, Ioana Creanga-Murariu iD, Réka Tóth, Eszter Ágnes Szalai iD, Mahmoud Obeidat iD, Szilárd Váncsa, Stefania Bunduc iD und 1 weitere

Cancers · 29.03.2026 · 18 (7) · 1108

DOI: 10.3390/cancers18071108 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 29.03.2026. Verfasst von Jázmin Németh und 12 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Translational Medicine, Semmelweis University, 1085 Budapest, Hungary. Die Arbeit nennt 72 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Centre for Translational Medicine at Semmelweis University, European Research Executive Agency, UEFISCDI.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: Cardiovascular diseases (CVDs) frequently limit the feasibility and effectiveness of cancer treatment. However, CVD burden has not been comprehensively described in pancreatic cancer. In our systematic review and meta-analysis, we evaluated the prevalence and incidence of CVDs in pancreatic ductal adenocarcinoma (PDAC).

Methods

We conducted the systematic search in PubMed, EMBASE, and CENTRAL on 5 February 2024. Studies reporting the prevalence or incidence of CVDs in PDAC were included. Subgroup analyses were performed based on cancer stage and treatment type. Pooled proportions with the 95% confidence interval (CI) were calculated using a random-effects model. (PROSPERO: CRD42023482295).

Results

We included 197 articles. At PDAC diagnosis, non-thrombotic cardiovascular diseases (NT-CVDs) were as prevalent as in the general population: hypertension in 33% (CI: 27–40%), ischemic heart disease in 6% (CI: 3–12%), and heart failure, arrhythmia, and stroke each in 2–3%. Their incidence during treatment remained low (1–10%). Thrombotic events, excluding pulmonary embolism, were present in 11% (CI: 7–15%) at diagnosis, with an incidence of 8–10% regardless of stage or treatment. Pulmonary embolism affected 3% at diagnosis and occurred at a similar rate during treatment.

Conclusions

Thromboembolic events are common in PDAC and occur both at diagnosis and during follow-up. Their incidence remains stable across treatment modalities and disease stages, suggesting that the tumor itself is the primary driver of thrombotic risk. The prevalence of NT-CVDs in PDAC is comparable to that in the general population and shows minimal variation across cancer stages or treatment modalities.

Schlagwörter

Stichwörter der Autor:innen

cardio-vascular eventsmeta-analysispancreatic cancerthromboembolism

Autor:innen und Institutionen

  • Centre for Translational Medicine, Semmelweis University, 1085 Budapest, Hungary.
  • Institute for Translational Medicine, Medical School, University of Pécs, 7622 Pécs, Hungary.
  • Department of Internal Medicine, Toldy Ferenc Hospital, 2700 Cegléd, Hungary.
  • Institute of Pancreatic Diseases, Semmelweis University, 1085 Budapest, Hungary.
  • Department of Medical Imaging, Bajcsy-Zsilinszky Hospital and Clinic, 1106 Budapest, Hungary.
  • Selye János Doctoral College for Advanced Studies, Semmelweis University, 1085 Budapest, Hungary.

ORCID-Profile: Jimin Lee, Endre Botond Gagyi, Zoltán Bánfalvi, Ioana Creanga-Murariu, Eszter Ágnes Szalai, Mahmoud Obeidat, Stefania Bunduc

Förderung

  • Centre for Translational Medicine at Semmelweis University
  • European Research Executive Agency
  • UEFISCDI
  • Centre for Translational Medicine at Semmelweis University, the Hungarian Ministry for Innovation and Technology, and the National Research, Development and In…
  • NKFIH
  • Semmelweis University Research and Innovation Fund
  • European Research Executive Agency https://ror.org/05mkt9r11
  • UEFISCDI and the Romanian Ministry of Education within the framework of NEW-TRIP

Zitieren

APA

Németh, J., Lee, J., Eperjesi, O., Gagyi, E. B., Bánfalvi, Z., Lillik, V., Creanga-Murariu, I., Tóth, R., Szalai, E. Á., Obeidat, M., Váncsa, S., Bunduc, S., & Hegyi, P. (2026). Cardiovascular Risk in Pancreatic Cancer: A Meta-Analysis of 197 Studies. Cancers, 18(7), 1108. https://doi.org/10.3390/cancers18071108

Vancouver

Németh J, Lee J, Eperjesi O, Gagyi EB, Bánfalvi Z, Lillik V, et al. Cardiovascular Risk in Pancreatic Cancer: A Meta-Analysis of 197 Studies. Cancers. 2026;18(7):1108. doi:10.3390/cancers18071108

BibTeX
@article{Nmeth2026,
  author = {Németh, Jázmin and Lee, Jimin and Eperjesi, Orsolya and Gagyi, Endre Botond and Bánfalvi, Zoltán and Lillik, Veronika and Creanga-Murariu, Ioana and Tóth, Réka and Szalai, Eszter Ágnes and Obeidat, Mahmoud and Váncsa, Szilárd and Bunduc, Stefania and Hegyi, Péter},
  title = {Cardiovascular Risk in Pancreatic Cancer: A Meta-Analysis of 197 Studies},
  journal = {Cancers},
  year = {2026},
  volume = {18},
  number = {7},
  pages = {1108},
  doi = {10.3390/cancers18071108}
}
Kostenlos starten →